| Year |
Citation |
Score |
| 2023 |
Li F, Ling X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, Liu X, Kalinski P, Tang DG. Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence. Journal of Experimental & Clinical Cancer Research : Cr. 42: 213. PMID 37596619 DOI: 10.1186/s13046-023-02787-x |
0.365 |
|
| 2020 |
Ling X, Wu W, Liao J, Santha S, Aljahdali L, Wang J, Fountzilas C, Iyer RV, Boland PM, Li F. Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment. Journal of Clinical Oncology. 38: e16102-e16102. DOI: 10.1200/Jco.2020.38.15_Suppl.E16102 |
0.385 |
|
| 2020 |
Santha S, Aljahdali I, Rasam SS, Wang X, Ling X, Liao J, Wang J, Fountzilas C, Li Q, Qu J, Li F. Role of mutant KRAS as a biomarker in FL118-induced apoptosis, reactive oxygen species (ROS) production and inhibition of survivin, Mcl-1 and XIAP in human bladder cancer. Journal of Clinical Oncology. 38: e15651-e15651. DOI: 10.1200/Jco.2020.38.15_Suppl.E15651 |
0.44 |
|
| 2019 |
Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? Journal of Experimental & Clinical Cancer Research : Cr. 38: 368. PMID 31439015 DOI: 10.1186/S13046-019-1362-1 |
0.394 |
|
| 2018 |
Rabi T, Li F. Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. American Journal of Cancer Research. 8: 2267-2283. PMID 30555743 |
0.324 |
|
| 2018 |
Ling X, Wu W, Fan C, Xu C, Liao J, Rich LJ, Huang RY, Repasky EA, Wang X, Li F. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. Journal of Experimental & Clinical Cancer Research : Cr. 37: 240. PMID 30285798 DOI: 10.1186/S13046-018-0899-8 |
0.383 |
|
| 2018 |
Wolff DW, Lee MH, Jothi M, Mal M, Li F, Mal AK. Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. Oncotarget. 9: 25796-25807. PMID 29899822 DOI: 10.18632/Oncotarget.25376 |
0.416 |
|
| 2015 |
Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. Journal of Experimental & Clinical Cancer Research : Cr. 34: 159. PMID 26714461 DOI: 10.1186/S13046-015-0275-X |
0.332 |
|
| 2015 |
Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M, Li F. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Molecular Cancer. 14: 92. PMID 25928015 DOI: 10.1186/S12943-015-0362-9 |
0.407 |
|
| 2014 |
Ling X, Xu C, Fan C, Zhong K, Li F, Wang X. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Research. 74: 7487-97. PMID 25512388 DOI: 10.1158/0008-5472.Can-14-0683 |
0.438 |
|
| 2014 |
Galloway NR, Diaz Osterman CJ, Reiber K, Jutzy JMS, Li F, Sui G, Soto U, Wall NR. Yin Yang 1 regulates the transcriptional repression of survivin Biochemical and Biophysical Research Communications. 445: 208-213. PMID 24508259 DOI: 10.1016/J.Bbrc.2014.01.169 |
0.445 |
|
| 2014 |
Haller AC, Tan W, Payne-Ondracek R, Underwood W, Tian L, Morrison C, Li F. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. The Prostate. 74: 509-19. PMID 24375440 DOI: 10.1002/Pros.22770 |
0.763 |
|
| 2014 |
Zhao J, Ling X, Cao S, Liu X, Wan S, Jiang T, Li F. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Molecular Pharmaceutics. 11: 457-67. PMID 24329001 DOI: 10.1021/Mp4004282 |
0.44 |
|
| 2014 |
Westover D, Ling X, Liu X, Lam H, Gongora C, Rio MD, Li F. Abstract 829: The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer Cancer Research. 74: 829-829. DOI: 10.1158/1538-7445.Am2014-829 |
0.454 |
|
| 2014 |
Ling X, Gandhi N, Jiao B, Chandra D, Li F. Abstract 802: Synergistic effect of curcumin on FL118 efficacy in colon cancer Cancer Research. 74: 802-802. DOI: 10.1158/1538-7445.Am2014-802 |
0.464 |
|
| 2014 |
Li F, Ling X, Westover D, Liu X, Jin C, Wani M. Abstract 1627: The novel camptothecin analog and antiapoptotic protein inhibitor FL118 appears to be a great backbone platform for development of personalized anticancer drugs Cancer Research. 74: 1627-1627. DOI: 10.1158/1538-7445.Am2014-1627 |
0.466 |
|
| 2013 |
Li F. Discovery of survivin inhibitors and beyond: FL118 as a proof of concept. International Review of Cell and Molecular Biology. 305: 217-52. PMID 23890383 DOI: 10.1016/B978-0-12-407695-2.00005-6 |
0.411 |
|
| 2013 |
Li F, Cao S, Ling X. Abstract 3446: FL118, a survivin/Mcl-1/XIAP/cIAP2-selective inhibitor, effectively inhibits human mesothelioma xenograft growth in animal models. Cancer Research. 73: 3446-3446. DOI: 10.1158/1538-7445.Am2013-3446 |
0.335 |
|
| 2012 |
Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. Plos One. 7: e45571. PMID 23029106 DOI: 10.1371/Journal.Pone.0045571 |
0.465 |
|
| 2012 |
Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, Li F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. International Journal of Biochemistry and Molecular Biology. 3: 179-97. PMID 22773958 |
0.763 |
|
| 2012 |
Tang L, Ling X, Liu W, Das GM, Li F. Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor. Biochemical and Biophysical Research Communications. 421: 249-54. PMID 22503977 DOI: 10.1016/J.Bbrc.2012.03.147 |
0.453 |
|
| 2012 |
Ling X, Westover D, Cao F, Cao S, Li F. Abstract 3726: Allyl isothiocyanate (AITC), a naturally occurring compound, combined with platinum-based therapies enhances apoptosisin vitro, and inhibits lung tumor growthin vivo Cancer Research. 72: 3726-3726. DOI: 10.1158/1538-7445.Am2012-3726 |
0.417 |
|
| 2012 |
Haller AC, Morrison C, Tan W, Payne-Ondracek R, Underwood W, Poch M, Tian L, Mohler J, Li F. Abstract 3637: Loss of prostate derived Ets (E-twenty six) transcription factor (PDEF) predicts patients at the highest risk of metastatic prostate cancer Cancer Research. 72: 3637-3637. DOI: 10.1158/1538-7445.Am2012-3637 |
0.754 |
|
| 2012 |
haller AC, Li F. Abstract 2871: Inhibition of androgen receptor-mediated expression of prostate derived ets transcription factor (PDEF) induces a loss of prostate cancer cell differentiation Cancer Research. 72: 2871-2871. DOI: 10.1158/1538-7445.Am2012-2871 |
0.781 |
|
| 2011 |
Ghadersohi A, Sharma S, Zhang S, Azrak RG, Wilding GE, Manjili MH, Li F. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. The Prostate. 71: 1178-88. PMID 21656828 DOI: 10.1002/Pros.21333 |
0.472 |
|
| 2011 |
Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2: 222-33. PMID 21447859 DOI: 10.18632/Oncotarget.248 |
0.751 |
|
| 2011 |
Li F, Ling X, Cao S, Cheng Q. Abstract 4525: Discovery and characterization of a small chemical compound that shows exceptional antitumor activity and targets multiple antiapoptotic proteins in the inhibitor of apoptosis (IAP) and Bcl-2 families Cancer Research. 71: 4525-4525. DOI: 10.1158/1538-7445.Am2011-4525 |
0.425 |
|
| 2011 |
Haller AC, Morrison C, Payne-Ondracek R, Tan W, Tian L, Mohler J, Li F. Abstract 4173: Prostate derived Ets (E-twenty six) transcription factor (PDEF) as a prognostic biomarker for metastatic prostate cancer Cancer Research. 71: 4173-4173. DOI: 10.1158/1538-7445.Am2011-4173 |
0.775 |
|
| 2011 |
Tang L, Ling X, Liu W, Das GM, Li F. Abstract 2178: Survivin appears to act as a transcription factor or co-factor to transcriptionally downregulate p21 gene expression via a p53 status-dependent manner Cancer Research. 71: 2178-2178. DOI: 10.1158/1538-7445.Am2011-2178 |
0.453 |
|
| 2010 |
Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, Kopecko DJ, Kalvakolanu DV, Li Y, Xu DQ. Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Therapy. 17: 844-54. PMID 20706288 DOI: 10.1038/cgt.2010.41 |
0.415 |
|
| 2010 |
Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, Johnson CS, Rustum YM, Porter CW. Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: Survivin expression overlaps with stem cell markers American Journal of Pathology. 176: 1629-1638. PMID 20133811 DOI: 10.2353/Ajpath.2010.090414 |
0.35 |
|
| 2010 |
Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. Journal of Experimental & Clinical Cancer Research : Cr. 29: 8. PMID 20096120 DOI: 10.1186/1756-9966-29-8 |
0.479 |
|
| 2009 |
Ling X, He X, Apontes P, Cao F, Azrak RG, Li F. Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. American Journal of Translational Research. 1: 393-405. PMID 19956451 |
0.756 |
|
| 2008 |
Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients International Journal of Cancer. 123: 1376-1384. PMID 18567002 DOI: 10.1002/Ijc.23667 |
0.509 |
|
| 2008 |
Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Molecular Cancer Therapeutics. 7: 1101-9. PMID 18483299 DOI: 10.1158/1535-7163.Mct-08-0179 |
0.453 |
|
| 2008 |
Raj D, Liu T, Samadashwily G, Li F, Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis. 29: 194-201. PMID 17916908 DOI: 10.1093/Carcin/Bgm219 |
0.444 |
|
| 2007 |
Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Molecular Cancer Therapeutics. 6: 2572-80. PMID 17876054 DOI: 10.1158/1535-7163.MCT-07-0172 |
0.45 |
|
| 2007 |
Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research. 67: 7746-55. PMID 17699779 DOI: 10.1158/0008-5472.Can-06-3724 |
0.436 |
|
| 2007 |
Ling X, Cheng Q, Black JD, Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. The Journal of Biological Chemistry. 282: 27204-14. PMID 17656368 DOI: 10.1074/Jbc.M705161200 |
0.383 |
|
| 2007 |
Wu J, Apontes P, Song L, Liang P, Yang L, Li F. Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Research. 35: 2390-402. PMID 17392340 DOI: 10.1093/nar/gkm149 |
0.74 |
|
| 2007 |
Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Research and Treatment. 102: 19-30. PMID 16897429 DOI: 10.1007/S10549-006-9314-9 |
0.496 |
|
| 2006 |
Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Molecular Cancer Therapeutics. 5: 2540-8. PMID 17041098 DOI: 10.1158/1535-7163.Mct-05-0546 |
0.484 |
|
| 2006 |
Li F, Brattain MG. Role of the Survivin gene in pathophysiology. The American Journal of Pathology. 169: 1-11. PMID 16816356 DOI: 10.2353/Ajpath.2006.060121 |
0.412 |
|
| 2006 |
Li F, Ling X. Survivin study: an update of "what is the next wave"? Journal of Cellular Physiology. 208: 476-86. PMID 16557517 DOI: 10.1002/Jcp.20634 |
0.326 |
|
| 2005 |
Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F. Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC) Lung Cancer. 49: 353-361. PMID 15936846 DOI: 10.1016/J.Lungcan.2005.03.037 |
0.437 |
|
| 2005 |
Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. The Journal of Biological Chemistry. 280: 9745-51. PMID 15637054 DOI: 10.1074/Jbc.M409350200 |
0.767 |
|
| 2005 |
Li F. Role of survivin and its splice variants in tumorigenesis British Journal of Cancer. 92: 212-216. PMID 15611788 DOI: 10.1038/Sj.Bjc.6602340 |
0.416 |
|
| 2005 |
Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene. 24: 1385-95. PMID 15608672 DOI: 10.1038/Sj.Onc.1208330 |
0.755 |
|
| 2005 |
Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? International Journal of Cancer. Journal International Du Cancer. 114: 509-12. PMID 15578717 DOI: 10.1002/Ijc.20768 |
0.391 |
|
| 2004 |
Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepato-Gastroenterology. 51: 1653-7. PMID 15532797 |
0.3 |
|
| 2004 |
Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 23: 7545-51. PMID 15334064 DOI: 10.1182/Blood.V104.11.3497.3497 |
0.397 |
|
| 2004 |
Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. The Journal of Biological Chemistry. 279: 15196-203. PMID 14722122 DOI: 10.1074/Jbc.M310947200 |
0.458 |
|
| 2003 |
Li F. Survivin study: what is the next wave? Journal of Cellular Physiology. 197: 8-29. PMID 12942537 DOI: 10.1002/Jcp.10327 |
0.389 |
|
| 2002 |
Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. The Journal of Pharmacology and Experimental Therapeutics. 303: 124-31. PMID 12235242 DOI: 10.1124/Jpet.102.037192 |
0.418 |
|
| 2001 |
Mahboubi K, Li F, Plescia J, Kirkiles-Smith NC, Mesri M, Du Y, Carroll JM, Elias JA, Altieri DC, Pober JS. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Laboratory Investigation; a Journal of Technical Methods and Pathology. 81: 327-34. PMID 11310826 DOI: 10.1038/Labinvest.3780241 |
0.305 |
|
| 2000 |
O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences of the United States of America. 97: 13103-13107. PMID 11069302 DOI: 10.1073/Pnas.240390697 |
0.391 |
|
| 2000 |
Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. The Journal of Biological Chemistry. 275: 9102-5. PMID 10734041 DOI: 10.1074/Jbc.275.13.9102 |
0.342 |
|
| 2000 |
Li F, Flanary PL, Altieri DC, Dohlman HG. Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast Journal of Biological Chemistry. 275: 6707-6711. PMID 10702224 DOI: 10.1074/Jbc.275.10.6707 |
0.383 |
|
| 2000 |
O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. The American Journal of Pathology. 156: 393-8. PMID 10666367 DOI: 10.1016/S0002-9440(10)64742-6 |
0.375 |
|
| 2000 |
Muchmore SW, Chen J, Jakob C, Zakula D, Matayoshi ED, Wu W, Zhang H, Li F, Ng S, Altieri DC. Crystal Structure and Mutagenic Analysis of the Inhibitor-of-Apoptosis Protein Survivin Molecular Cell. 6: 173-182. DOI: 10.1016/S1097-2765(05)00019-5 |
0.347 |
|
| 1999 |
Grossman D, McNiff JM, Li F, Altieri DC. Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma Journal of Investigative Dermatology. 113: 1076-1081. PMID 10594755 DOI: 10.1046/J.1523-1747.1999.00776.X |
0.409 |
|
| 1999 |
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396: 580-4. PMID 9859993 DOI: 10.1038/25141 |
0.396 |
|
| 1999 |
Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochemical Journal. 344: 305-311. DOI: 10.1042/Bj3440305 |
0.41 |
|
| 1998 |
Papadaki M, Ruef J, Nguyen KT, Li F, Patterson C, Eskin SG, McIntire LV, Runge MS. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. Circulation Research. 83: 1027-34. PMID 9815150 DOI: 10.1161/01.Res.83.10.1027 |
0.31 |
|
| 1998 |
Ruef J, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A, Runge MS. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation. 97: 1071-8. PMID 9531254 DOI: 10.1161/01.Cir.97.11.1071 |
0.336 |
|
| 1997 |
Wang HS, Li F, Runge MS, Chaikof EL. Endothelial cells exhibit differential chemokinetic and mitogenic responsiveness to α-thrombin Journal of Surgical Research. 68: 139-144. PMID 9184672 DOI: 10.1006/Jsre.1997.5044 |
0.343 |
|
| 1996 |
Li F, Baykal D, Horaist C, Yan CN, Carr BN, Rao GN, Runge MS. Cloning and identification of regulatory sequences of the human thrombin receptor gene Journal of Biological Chemistry. 271: 26320-26328. PMID 8824285 DOI: 10.1074/Jbc.271.42.26320 |
0.345 |
|
| 1995 |
Runge MS, Schmedtje JF, Horaist C, Li F, Wilcox JN, Bode C. New approaches to inhibiting thrombin's effect on the blood vessel wall Fibrinolysis and Proteolysis. 9: 69-73. DOI: 10.1016/S0268-9499(08)80015-X |
0.315 |
|
| Show low-probability matches. |